secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010541
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025
--------------------------------------------------------------------------------

- Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
- Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.
- LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.
- FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.
- LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/0001641172-25-010541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225010541/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer